FLT3 Inhibition in Acute Myeloid Leukemia.

doi:10.1016/S2152-2650(20)30441-9

Back to search

Article

FLT3 Inhibition in Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia - 1 Sept 2020

Smith Catherine C

Abstract excerpt

Mutations in the FLT3 receptor tyrosine kinase are the most frequently found mutations in acute myeloid leukemia (AML). Patients with FLT3 internal tandem duplication (ITD) mutations have poor prognoses. The approved FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and gilteritinib improve surv...

Topics

Clinical Trials, Phase III as Topic
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Randomized Controlled Trials as Topic
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.